Additionally, TMPRSS2-ERG fusions exist in approximately 50% of prostate cancer cases, with TMPRSS2-FEV, -ETV1, -ETV4, and -ETV5 fusions found in other patients [36]. Here, ETV4 is linked to prostate cancer.